The short version of melanotan-2 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-31 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
While A, T, C, and G represent a particular nucleotide at a position, there are also letters that represent ambiguity which are used when more than one kind of nucleotide could occur at that position. The rules of the International Union of Pure and Applied Chemistry (IUPAC) are as follows: For example, W means that either an adenine or a thymine could occur in that position without impairing the sequence's functionality.
== Sample preparation and extraction == The bioanalyst deals with complex biological samples containing the analyte alongside a diverse range of chemicals that can have an adverse impact on the accurate and precise quantification of the analyte. As such, a wide range of techniques are applied to extract the analyte from its matrix. These include:
Among the extreme claims used to market goji berries or its juice, often referred to as a "superfruit", is the unsupported story that a Chinese man named Li Qing Yuen, who was said to have consumed wolfberries daily, lived to the age of 256 years (1677–1933). This claim originated in a 2003 booklet by Mindell, who also claimed goji had anti-cancer properties. The booklet contained false and unverified claims. On 29 May 2009, a class action lawsuit was filed against FreeLife in the United States District Court of Arizona. This lawsuit alleged false claims, misrepresentations, false and deceptive advertising, and other issues regarding FreeLife's Himalayan Goji Juice, GoChi, and TaiSlim products. This lawsuit sought remedies for consumers who had purchased the products over the years. A settlement agreement was reached on 28 April 2010, where FreeLife took steps to ensure that its goji products were not marketed as "unheated" or "raw", and made a contribution to an educational organization. As with many other novel "health" foods and supplements, the lack of clinical evidence and poor quality control in the manufacture of consumer products prevent goji from being clinically recommended or applied.
The human and animal data consistently indicate a lack of carcinogenicity via the oral route of exposure and limit the carcinogenicity of nickel compounds to respiratory tumours after inhalation. Nickel metal is classified as a suspect carcinogen; there is consistency between the absence of increased respiratory cancer risks in workers predominantly exposed to metallic nickel and the lack of respiratory tumours in a rat lifetime inhalation carcinogenicity study with nickel metal powder. In the rodent inhalation studies with various nickel compounds and nickel metal, increased lung inflammations with and without bronchial lymph node hyperplasia or fibrosis were observed. In rat studies, oral ingestion of water-soluble nickel salts can trigger perinatal mortality in pregnant animals. Whether these effects are relevant to humans is unclear as epidemiological studies of highly exposed female workers have not shown adverse developmental toxicity effects. People can be exposed to nickel in the workplace by inhalation, ingestion, and contact with skin or eye. The Occupational Safety and Health Administration (OSHA) has set the legal limit (permissible exposure limit) for the workplace at 1 mg/m3 per 8-hour workday, excluding nickel carbonyl. The National Institute for Occupational Safety and Health (NIOSH) sets the recommended exposure limit (REL) at 0.015 mg/m3 per 8-hour workday. At 10 mg/m3, nickel is immediately dangerous to life and health. Nickel carbonyl [Ni(CO)4] is an extremely toxic gas.
Sources: en.wikipedia.org
Xylazine is widely used in veterinary medicine as a sedative, muscle relaxant, and analgesic. It is frequently used in the treatment of tetanus. It is not used in human medical treatment. Xylazine is similar to drugs such as phenothiazines, tricyclic antidepressants, and clonidine. As an anesthetic, it is typically used in conjunction with ketamine. In animals, xylazine may be administered intramuscularly, intravenously, and intraosseously. Subcutaneous, oral transmusocal and intranasal have been investigated but are not standard routes for xylazine administration. As a veterinary anesthetic, xylazine is typically only administered once for the intended effect before or during surgical procedures. α2-Adrenergic receptor antagonists such as atipamezole and yohimbine may be used to reverse the effects of xylazine in animals. Xylazine is licensed for use in non-meat horses. Off-label use in cattle is common with recommended withholding periods of 1–5 days for dairy cattle and 4–10 days for meat cattle. Cattle are more sensitive to xylazine than horses with the sensitivity being greater in meat cattle breeds than dairy cattle breeds. Xylazine's use in cats and dogs is being replaced with the more selective alpha2 adrenergic receptor agonists medetomidine and dexmedetomidine and in some countries xylazine is rarely used with cats and dogs. High amounts of catecholamines in a patient will require higher doses of xylazine to be administered to provide sedation. The heightened levels required may not be practical or possible to administer and regular doses may cause excitement.
=== 5q- myelodysplastic syndrome === 5q- myelodysplastic syndrome (MDS) is associated with acquired haplo-insufficiency of RPS14, a component of the eukaryotic small ribosomal subunit (40S). RPS14 is critical for 40S assembly, and depletion of RPS14 in human CD34(+) cells is sufficient to recapitulate the 5q- defect of erythropoiesis with sparing of megakaryocytes.
Involuntary sterilization programs were in some instances supported and funded by the states. In California, the rationale for forced sterilization was primarily for eugenics purposes, although this later shifted to a fear of overpopulation and welfare dependency. California passed the third law in the United States that allowed state institutions to sterilize "unfit" and "feeble-minded" individuals. As eugenics gained credibility as a field in science, sterilization rates increased, especially after the 1927 Buck v. Bell U.S. Supreme Court decision, which upheld the constitutionality of sterilization laws in Virginia. See below. According to available data, California performed one third of all reported sterilization procedures in the United States between 1910 and 1960. Although the Californian state was the third state to legalize sterilization as mentioned previously, it has made the greatest impact by performing over half of the sterilization procedures throughout the eugenics era from 1907 to 1979. Their laws granted prison authorities and asylum medical superintendents the right to sterilize a patient if it would be proven to better their conditions. It surpassed the other 32 states who had passed eugenics laws due to its large Latino incarceration rates and advocacy found within the eugenics movements. Between 1920 and 1945, over 17,000 individuals were recommended for sterilization in California. During this time, Latinas were at a 59% greater risk of being sterilized than non-Latinas.
== Name and discovery == The name Coomassie was adopted at the end of the 19th century as a trade name by the Blackley-based dye manufacturer Levinstein Ltd, in marketing a range of acid wool dyes. In 1896 during the Fourth Anglo–Ashanti War, British forces had occupied the town of Coomassie (modern-day Kumasi in Ghana). In 1918 Levinstein Ltd became part of British Dyestuffs, which in 1926 became part of Imperial Chemical Industries. Although ICI still owns the Coomassie trademark, the company no longer manufactures the dyes. The blue disulfonated triphenylmethane dyes were first produced in 1913 by Max Weiler, who was based in Elberfeld, Germany. Various patents were subsequently taken out on the organic synthesis. Papers published in biochemistry journals frequently refer to these dyes simply as "Coomassie" without specifying which dye was used. In fact, the Colour Index lists over 40 dyes with "Coomassie" in their name. There are also other Coomassie "blue" dyes. For example, the Merck Index (10th edition) lists Coomassie Blue RL (Acid Blue 92, C.I. 13390), which has a completely different structure.
=== Neodymium === The rare earth element Neodymium is extracted by di(2-ethyl-hexyl)phosphoric acid into hexane by an ion exchange mechanism. Neodymium can also be separated from dysprosium through selective precipitation of dysprosium with Cyanex 272 when the HNO3 concentration was 0.001 mol/L.
Sources: en.wikipedia.org
To identify the sodium-channel binding surface of d-ACTX-Ar1a, scientist must synthesize analogues with selected residue changes. Studies will contribute to a more detailed mapping of site-3, the neurotoxin receptor site on the sodium-channel and provide structure-activity data critical for determining the phyla-specific actions of this and related atracotoxins.
Beginning with his January 29, 2002 State of the Union address, Bush began publicly focusing attention on Iraq, which he labeled as part of an "axis of evil" allied with terrorists and posing "a grave and growing danger" to U.S. interests through possession of weapons of mass destruction. In the latter half of 2002, CIA reports contained assertions of Saddam Hussein's intent of reconstituting nuclear weapons programs, not properly accounting for Iraqi biological and chemical weapons, and that some Iraqi missiles had a range greater than allowed by the UN sanctions. Contentions that the Bush Administration manipulated or exaggerated the threat and evidence of Iraq's weapons of mass destruction capabilities would eventually become a major point of criticism for the president. In late 2002 and early 2003, Bush urged the United Nations to enforce Iraqi disarmament mandates, precipitating a diplomatic crisis. In November 2002, Hans Blix and Mohamed ElBaradei led UN weapons inspectors in Iraq, but were advised by the U.S. to depart the country four days prior to the U.S. invasion, despite their requests for more time to complete their tasks. The U.S. initially sought a UN Security Council resolution authorizing the use of military force but dropped the bid for UN approval due to vigorous opposition from several countries. The Bush administration's claim that the Iraq War was part of the war on terror had been questioned and contested by political analysts.
Inmates on Oklahoma's death row alleged that the use of midazolam was unconstitutional because the drug was not proven to render a person unconscious as thiobarbital would. The Supreme Court found that the prisoners failed to demonstrate that midazolam would create a high risk of severe pain and that the prisoners had not provided an alternative, practical method of execution that would have a lower risk. Consequently, it ruled that the new method was permissible under the Eighth Amendment. On March 15, 2018, Russell Bucklew, a Missouri death-row inmate who had been scheduled to be executed on May 21, 2014, appealed the constitutionality of lethal injection on an as-applied basis. The basis for Bucklew's appeal was due to Bucklew's allegation that his rare medical condition would interfere with the effects of the drugs, potentially causing him to choke on his blood. On April 1, 2019, The Supreme Court ruled against Bucklew on the grounds that his proposed alternative to lethal injection, nitrogen hypoxia, was neither "readily implemented" nor established to "significantly reduce a substantial risk of severe pain." Bucklew was executed on October 1, 2019.
=== Allegations of steroid use and National Baseball Hall of Fame === Bagwell was eligible for induction into the Baseball Hall of Fame for the first time in 2011. Speculation abounded that some baseball writers initially refrained from voting for Bagwell on the premise that he used performance-enhancing drugs, since most of his playing career took place during what is commonly referred to as "the steroid era." In spite of the speculation, as of 2016, no concrete evidence has surfaced linking him to the use of performance-enhancing drugs. However, one report indicates that he disclosed use of androstenedione to a Houston Chronicle reporter in 1998. At that time, neither the FDA nor MLB had banned its use. Bagwell has not been connected with any of the 104 positive samples in the 2003 survey tests that were leaked. Bagwell was not among the 89 players named in the Mitchell Report released in 2007. Longtime Atlanta Braves manager Bobby Cox said the following about Bagwell: "Jeff Bagwell was [in Houston] for so long and starred every year. For me a guy that dominated like that for one team, even in the league stats through the years. His are up there with anybody's. I would put him in right away. So he would get my vote on the first ballot." Still, in spite of the speculation that Bagwell used performance-enhancing drugs, San Francisco Chronicle sportswriter Bruce Jenkins wrote that Bagwell did not have the credentials to be in the Hall of Fame. In July 2015, he acknowledged "that many are suspicious of Bagwell—without proof, as you say.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.